Esperion Therapeutis.Inc. buy Heureka
Summary
This prediction ended on 10.02.20 with a price of €60.54. The BUY prediction by Heureka finished with a performance of 15.67%. Heureka has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Esperion Therapeutis.Inc. | -9.600% | -9.600% | 8.467% | -85.887% |
iShares Core DAX® | -3.429% | 5.085% | 15.455% | 12.600% |
iShares Nasdaq 100 | -6.121% | 0.593% | 16.379% | 27.048% |
iShares Nikkei 225® | -7.364% | 5.479% | 6.970% | -3.061% |
iShares S&P 500 | -4.366% | 2.019% | 18.650% | 32.317% |
Comments by Heureka for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
In the thread Trading Esperion Therapeutis.Inc.
Stopped prediction by Heureka for Esperion Therapeutis.Inc.
Esperion Therapeutis.Inc.
26.02.20
09.03.20
09.03.20